Synedica Cagri Sema Dual Injection Pen Kit – Semaglutide 4mg + Cagrilintide 4mg
Synedica Cagri Sema Dual Injection Pen Kit is a two-pen research kit containing Semaglutide 4mg in Pen 1 and Cagrilintide 4mg in Pen 2. The kit is designed for laboratory and scientific research involving GLP-1 and amylin-related signalling pathways.

CagriSema research focuses on the combination of two distinct peptide mechanisms: semaglutide, a GLP-1 analogue, and cagrilintide, a long-acting amylin analogue. This combination has been investigated in experimental and clinical research, including studies examining metabolic signalling and energy balance.
For research use only. Not for human or veterinary use.
Synedica Cagri Sema Dual Injection Pen Kit Overview
| Specification | Details |
|---|---|
| Product Name | Synedica Cagri Sema Dual Injection Pen Kit |
| Pen 1 | Semaglutide 4mg |
| Pen 2 | Cagrilintide 4mg |
| Format | Two-pen research kit |
| Research Category | Metabolic and Peptide Research |
| Intended Application | Laboratory and scientific research |
| Human Use | Not intended for human use |
What Is Synedica Cagri Sema?
Synedica Cagri Sema is a dual research peptide kit containing separate Semaglutide and Cagrilintide research pens. The two compounds are associated with different biological signalling pathways that are of interest in metabolic and peptide research.
Semaglutide is a long-acting GLP-1 analogue, while cagrilintide is a long-acting amylin analogue. Research into their combination provides scientists with an opportunity to investigate the interaction of GLP-1-related and amylin-related mechanisms in controlled experimental settings.
Semaglutide 4mg Research Pen
The first component of the Synedica Cagri Sema Dual Injection Pen Kit is the Semaglutide 4mg research pen.
Semaglutide is a peptide analogue associated with GLP-1 receptor activity. It has been extensively studied in metabolic and endocrine research, including research into glucose regulation, appetite-related signalling and energy balance.
For laboratory researchers, the Semaglutide component provides a defined research material for investigations involving GLP-1-related biological pathways.
Cagrilintide 4mg Research Pen
The second component is the Cagrilintide 4mg research pen.
Cagrilintide is a long-acting amylin analogue investigated in research involving appetite-related signalling, energy balance and metabolic pathways. Amylin signalling represents a separate biological pathway from GLP-1 signalling, making cagrilintide relevant to combination peptide research.
The separate Cagrilintide pen allows researchers to identify and document this component independently within their laboratory workflow.
CagriSema Research and Scientific Background
CagriSema refers to the combination of cagrilintide and semaglutide. Scientific research has examined this combination in experimental models as well as human clinical research settings.
A peer-reviewed study published in Nature Metabolism investigated CagriSema in rats and reported effects involving energy intake and energy expenditure. The study describes CagriSema as a combination of cagrilintide and semaglutide analogues. The findings are experimental animal data and should not be interpreted as evidence for the safety or suitability of a particular research product in humans.
For detailed scientific information, researchers can review the full publication in Nature Metabolism: CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.
Additional scientific background on combined amylin analogue and GLP-1 receptor agonist research is available through Nature Reviews Endocrinology: Combined amylin analogue and GLP1 receptor agonist therapies.
Research Applications
The Synedica Cagri Sema research kit may be relevant to appropriately equipped research environments investigating:
- GLP-1 receptor signalling
- Amylin-related signalling
- Peptide receptor pharmacology
- Metabolic pathway research
- Energy-balance mechanisms
- Appetite-related signalling
- Comparative peptide research
- Combination peptide research
- Experimental metabolic models
- GLP-1 and amylin pathway interactions
Dual-Pen Research Format
The Synedica Cagri Sema Dual Injection Pen Kit uses a two-pen format, keeping the Semaglutide and Cagrilintide research materials separately identifiable.
According to the current Synedica catalogue, Pen 1 contains Semaglutide 4mg and Pen 2 contains Cagrilintide 4mg.
This format can help researchers maintain clear product identification and documentation when conducting controlled laboratory research involving different peptide materials.
Research Quality and Laboratory Handling
Research peptide materials should be handled according to the applicable product documentation and laboratory procedures. Researchers should maintain appropriate records for product identification, storage and experimental use.
- Keep research materials correctly labelled.
- Follow the manufacturer’s supplied storage information.
- Protect materials from inappropriate environmental conditions.
- Use suitable laboratory handling procedures.
- Maintain appropriate research documentation.
- Keep research materials separate from products intended for clinical use.
Storage and Handling Information
Storage requirements can vary according to formulation, packaging and research workflow. Researchers should therefore follow the specific documentation supplied with the product rather than applying generic storage assumptions.
Research materials should be kept appropriately labelled and handled using established laboratory procedures designed to minimise contamination, degradation or accidental misuse.
Why Choose the Synedica Cagri Sema Research Kit?
The Synedica Cagri Sema Dual Injection Pen Kit provides researchers with two separately identified peptide research materials in one organised kit.
The combination of a Semaglutide 4mg research pen and a Cagrilintide 4mg research pen makes the kit relevant to research exploring GLP-1 and amylin-related biological pathways.
Researchers looking for additional Synedica products can explore the Synedica research peptide collection for additional research-focused products and kits.
Scientific Research Reference
Scientific literature provides important background when evaluating the mechanisms associated with CagriSema. A 2025 Nature Metabolism study examined CagriSema in rats, while a 2025 Nature Reviews Endocrinology article reviewed research involving combined amylin analogue and GLP-1 receptor agonist approaches.
These publications are provided as independent scientific references and should be interpreted within the limitations of their respective research designs. Experimental animal findings cannot automatically be transferred to human use.
Important Research-Use Disclaimer
For research use only. The Synedica Cagri Sema Dual Injection Pen Kit is presented as research material and is not intended for human or veterinary use.
The information provided on this page is intended for scientific and educational purposes. It does not constitute medical advice, treatment advice, prescribing guidance or instructions for human administration.
Semaglutide and Cagrilintide research should be conducted within an appropriately controlled research environment and according to applicable institutional procedures and laboratory safety requirements.
Frequently Asked Questions
What is Synedica Cagri Sema?
Synedica Cagri Sema is a two-pen research kit containing Semaglutide 4mg in Pen 1 and Cagrilintide 4mg in Pen 2.
How many pens are included in the Cagri Sema kit?
The Synedica Cagri Sema product is presented as a two-pen kit, with one Semaglutide research pen and one Cagrilintide research pen.
What is in Pen 1?
The current Synedica catalogue identifies Pen 1 as Semaglutide 4mg.
What is in Pen 2?
The current Synedica catalogue identifies Pen 2 as Cagrilintide 4mg.
What is CagriSema?
CagriSema refers to the combination of cagrilintide and semaglutide. Semaglutide is associated with GLP-1 receptor activity, while cagrilintide is a long-acting amylin analogue.
What is Semaglutide?
Semaglutide is a peptide analogue associated with GLP-1 receptor activity and is widely studied in metabolic and endocrine research.
What is Cagrilintide?
Cagrilintide is a long-acting amylin analogue investigated in research involving appetite-related signalling, energy balance and metabolic pathways.
Is the Synedica Cagri Sema kit for human use?
No. This product is presented as research material and is not intended for human or veterinary use.
Where can I find more Synedica research products?
You can explore the wider Synedica research products collection for additional peptide research products and kits.
Explore Synedica Research Products
Explore the Synedica collection for research-focused peptide kits and other laboratory research materials.









Reviews
There are no reviews yet.